Kalaris Therapeutics (NASDAQ:KLRS) Raised to “Hold” at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Tuesday.

Kalaris Therapeutics Stock Up 0.4%

NASDAQ KLRS opened at $2.57 on Tuesday. Kalaris Therapeutics has a 12 month low of $2.45 and a 12 month high of $24.15.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.